CCL2 chemokine inhibition primes the tumor vasculature for improved nanomedicine delivery and efficacy-Reference-Cited by-同舟云学术

CCL2 chemokine inhibition primes the tumor vasculature for improved nanomedicine delivery and efficacy

Published:2024-01 Issue: Volume:365 Page:358-368
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Möckel Diana,Bartneck Matthias,Niemietz Patricia,Wagner Maike,Ehling Josef,Rama Elena,Weiler Marek,Gremse Felix,Eulberg Dirk,Pola Robert,Pechar Michal,Etrych Tomas,Storm Gert,Kiessling Fabian,Tacke Frank,Lammers Twan

Funder

Deutsche Forschungsgemeinschaft

Ministerstvo Zdravotnictví Ceské Republiky

Wilhelm Sander-Stiftung

European Research Council

ERC

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference56 articles.

1. Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy;Bridges;Cancer Cell,2015

2. The tumor microenvironment and strategies to improve drug distribution;Saggar;Front. Oncol.,2013

3. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications;Rizzo;Curr. Opin. Biotechnol.,2013

4. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress;Lammers;J. Control. Release,2012

5. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application;Wu;J. Pers. Med.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis;Journal of Experimental & Clinical Cancer Research;2024-07-22

2. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment;Microvascular Research;2024-07

3. Tumor-penetrating iRGD facilitates penetration of poly(floxuridine-ketal)-based nanomedicine for enhanced pancreatic cancer therapy;Journal of Controlled Release;2024-05

4. Advances in erlotinib delivery systems: Addressing challenges and exploring opportunities in EGFR-targeted cancer therapies;Inorganic Chemistry Communications;2024-03

5. Research Progress of Nano-Drugs Remodeling TAMs for Enhancing Cancer Immunotherapy;Advances in Clinical Medicine;2024